Practical Fragments

Just over two years ago we highlighted a new clinical candidate targeting WRN, a covalent inhibitor then called VVD-133214. An open-access ...

It’s been a couple years since Practical Fragments last updated our “fragments in the clinic” list . Before doing so it makes sense to high...

Last week’s CHI Drug Discovery Chemistry (DDC) meeting was held as usual in San Diego. More than 850 people attended, 96% in person, with 7...

As the title states, this is the 1000 th post at Practical Fragments . This blog was conceived in 2008 over drinks at the Third Annual CHI ...

At the end of 2023 I mentioned that a paper by Dean Brown listed berotralstat as a fragment-derived drug. Readers will notice this molecule...

Back in 2016 we highlighted a paper describing chemoproteomic screening of covalent fragments. That technology formed the basis of Vividion...

It has been more than a year since our last list of fragment-derived clinical compounds. Since then capivasertib has been approved, bringi...

On Thursday last week the FDA approved capivasertib for certain breast cancer patients. This marks the seventh fragment-derived drug to be...

Just over seven years ago Practical Fragments highlighted work out of Merck describing the discovery and optimization of potent, selective ...

The winter solstice is behind us in the Northern Hemisphere, which means 2022 is rapidly drawing to a close. As we have done for the past d...

In the US we're about to celebrate Thanksgiving . One of the things I'm thankful for is the discovery of new medicines, so this seem...

Last week the CHI Drug Discovery Chemistry (DDC) meeting returned triumphantly to San Diego. This was the best conference I’ve attended in ...